Northwest Biotherapeutics, Inc. (NWBO)
OTCMKTS · Delayed Price · Currency is USD
0.1785
-0.0015 (-0.83%)
Aug 19, 2026, 3:47 PM EST
Northwest Biotherapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 2.17 | 1.38 | 1.38 | 1.93 | 1.68 | 1.01 | |
Revenue Growth | 98.63% | -0.29% | -28.47% | 14.79% | 67.46% | -22.15% |
Cost of Revenue | 23.57 | 28.79 | 34.89 | 27.73 | 35.51 | 20.31 |
Gross Profit | -21.39 | -27.41 | -33.51 | -25.8 | -33.83 | -19.3 |
Selling, General & Admin | 28.94 | 32.51 | 33 | 29.71 | 33.35 | 33.4 |
Operating Expenses | 28.94 | 32.51 | 33 | 29.71 | 33.35 | 33.4 |
Operating Income | -50.33 | -59.91 | -66.51 | -55.51 | -67.18 | -52.7 |
Interest Expense | -9.42 | -8.7 | -7.77 | -5.24 | -6.07 | -5.01 |
Currency Exchange Gain (Loss) | -2.09 | 4.92 | -1.55 | 2.01 | -3.3 | -1.7 |
Other Non Operating Income (Expenses) | 7.29 | -0.57 | -0.44 | 3.57 | -25.79 | 238.7 |
EBT Excluding Unusual Items | -54.55 | -64.26 | -76.27 | -55.18 | -102.34 | 179.29 |
Other Unusual Items | 16.29 | 3.56 | -7.51 | -7.42 | -2.69 | -0.17 |
Pretax Income | -38.27 | -60.7 | -83.78 | -62.6 | -105.03 | 179.13 |
Income Tax Expense | -0.54 | -0.54 | - | - | - | - |
Net Income | -37.73 | -60.16 | -83.78 | -62.6 | -105.03 | 179.13 |
Preferred Dividends & Other Adjustments | 1.48 | 1.32 | 1.41 | 1.77 | - | - |
Net Income to Common | -39.21 | -61.48 | -85.19 | -64.37 | -105.03 | 179.13 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 1,564 | 1,457 | 1,242 | 1,119 | 1,016 | 874 |
Shares Outstanding (Diluted) | 1,564 | 1,457 | 1,242 | 1,119 | 1,016 | 1,008 |
Shares Change | 16.62% | 17.26% | 10.99% | 10.17% | 0.79% | 38.99% |
EPS (Basic) | -0.03 | -0.04 | -0.07 | -0.06 | -0.10 | 0.21 |
EPS (Diluted) | -0.03 | -0.04 | -0.07 | -0.06 | -0.10 | -0.06 |
EPS Growth | - | - | - | - | - | - |
Free Cash Flow | -49.77 | -46.27 | -58.03 | -57.07 | -55.68 | -44.31 |
Free Cash Flow Per Share | -0.03 | -0.03 | -0.05 | -0.05 | -0.06 | -0.04 |
Operating Margin | -2316.11% | -4347.90% | -4812.45% | -2873.09% | -3991.74% | -5243.98% |
Profit Margin | -1804.37% | -4461.32% | -6164.40% | -3331.94% | -6240.76% | 17823.48% |
Free Cash Flow Margin | -2290.34% | -3357.55% | -4199.06% | -2954.14% | -3308.20% | -4409.35% |
EBITDA | -47.61 | -57.85 | -64.76 | -53.98 | -65.93 | -52.38 |
D&A For EBITDA | 2.72 | 2.06 | 1.74 | 1.53 | 1.25 | 0.32 |
EBIT | -50.33 | -59.91 | -66.51 | -55.51 | -67.18 | -52.7 |
Revenue as Reported | 2.17 | 1.38 | 1.38 | 1.93 | 1.68 | 1.01 |